A study to compare the efficacy of AZD2171 [cediranib; Recentin; AstraZeneca] in combination with 5-fluorouracil, leucovorin [folinic acid], and oxaliplatin (FOLFOX) and the efficacy of bevacizumab [Avastin] in combination with FOLFOX in the second-line treatment of patients with metastatic colorectal cancer.

Trial Profile

A study to compare the efficacy of AZD2171 [cediranib; Recentin; AstraZeneca] in combination with 5-fluorouracil, leucovorin [folinic acid], and oxaliplatin (FOLFOX) and the efficacy of bevacizumab [Avastin] in combination with FOLFOX in the second-line treatment of patients with metastatic colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Cediranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HORIZON-I
  • Most Recent Events

    • 22 Jan 2011 Results of an analysis investigating prognostic markers of response presented at the 2011 Gastrointestinal Cancers Symposium.
    • 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top